Get the Stockscreener App
37.26
1.11%
0.41
After Hours:
37.25
-0.010
-0.03%
Royalty Pharma Plc stock is traded at $37.26, with a volume of 1.75M.
It is up +1.11% in the last 24 hours and up +4.17% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$36.85
Open:
$36.85
24h Volume:
1.75M
Relative Volume:
0.47
Market Cap:
$16.11B
Revenue:
$2.31B
Net Income/Loss:
$1.66B
P/E Ratio:
16.22
EPS:
2.297
Net Cash Flow:
$827.02M
1W Performance:
+0.68%
1M Performance:
+4.17%
6M Performance:
+16.33%
1Y Performance:
+36.58%
1-Day Range:
$36.85
$37.40
1-Week Range:
$36.11
$37.69
52-Week Range:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
37.26 | 15.93B | 2.31B | 1.66B | 827.02M | 2.297 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Weiss Ratings Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold (C+) - MarketBeat
Is Royalty Pharma plc (RPD) stock a buy during volatile marketsGap Down & Detailed Earnings Play Alerts - newser.com
Can Royalty Pharma plc stock beat analyst upgradesJuly 2025 Setups & Verified Momentum Stock Watchlist - newser.com
What the charts say about Royalty Pharma plc todayOil Prices & Real-Time Stock Entry Alerts - newser.com
Using Python tools to backtest Royalty Pharma plc strategies2025 Technical Patterns & AI Driven Price Predictions - newser.com
Is Royalty Pharma plc reversing from oversold territoryMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Why Royalty Pharma plc (RPD) stock could outperform next yearJuly 2025 Movers & Verified Chart Pattern Trade Signals - newser.com
Why retail investors pile into Royalty Pharma plc stockAnalyst Upgrade & Short-Term High Return Strategies - newser.com
What indicators show strength in Royalty Pharma plcGap Down & Verified Momentum Stock Watchlist - newser.com
What’s the recovery path for long term holders of Royalty Pharma plcJuly 2025 Sentiment & Low Drawdown Momentum Trade Ideas - newser.com
Why Royalty Pharma plc (RPD) stock could rally strongly2025 Key Highlights & Smart Money Movement Alerts - newser.com
What to Know Before Buying the Dip in SPEL Semiconductor LimitedTrend Following Strategies & Free Phenomenal Trading Returns - earlytimes.in
What Drawdown Risk Means for Long Term Holders of Innomet Advanced Materials LimitedCurrency Fluctuation Impact & Low Risk Trading Portfolio - earlytimes.in
Rehmann Capital Advisory Group Sells 8,893 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Does Royalty Pharma plc qualify in momentum factor screeningGap Down & Long-Term Investment Growth Plans - newser.com
Detecting support and resistance levels for Royalty Pharma plcJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):